Equities analysts expect CVS Health Corp (NYSE:CVS) to post earnings per share of $1.77 for the current fiscal quarter, according to Zacks Investment Research. Twenty Four analysts have provided estimates for CVS Health’s earnings, with the highest EPS estimate coming in at $1.80 and the lowest estimate coming in at $1.68. CVS Health posted earnings of $1.73 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 2.3%. The firm is expected to report its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that CVS Health will report full year earnings of $6.96 per share for the current fiscal year, with EPS estimates ranging from $6.85 to $7.00. For the next year, analysts expect that the company will report earnings of $7.18 per share, with EPS estimates ranging from $7.05 to $7.38. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow CVS Health.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.70 by $0.19. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The business had revenue of $63.43 billion during the quarter, compared to analysts’ expectations of $62.66 billion. During the same quarter in the prior year, the business earned $1.69 earnings per share. The company’s quarterly revenue was up 35.2% compared to the same quarter last year.

A number of equities analysts have commented on CVS shares. ValuEngine cut shares of CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. Morgan Stanley reissued a “buy” rating and set a $74.00 price target on shares of CVS Health in a report on Sunday, August 11th. Standpoint Research raised shares of CVS Health from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. Citigroup raised their price objective on shares of CVS Health from $68.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Mizuho set a $71.00 price objective on CVS Health and gave the company a “buy” rating in a report on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $75.18.

Several large investors have recently made changes to their positions in CVS. Bay Harbor Wealth Management LLC raised its stake in shares of CVS Health by 1,871.4% during the 1st quarter. Bay Harbor Wealth Management LLC now owns 552 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 524 shares during the last quarter. Executive Wealth Management LLC increased its holdings in CVS Health by 62.4% during the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 217 shares in the last quarter. Manchester Financial Inc. acquired a new position in CVS Health during the second quarter worth about $31,000. Hudock Capital Group LLC raised its position in CVS Health by 54.0% during the second quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 202 shares during the last quarter. Finally, Tarbox Family Office Inc. raised its position in CVS Health by 74.7% during the second quarter. Tarbox Family Office Inc. now owns 580 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 248 shares during the last quarter. 76.06% of the stock is currently owned by institutional investors and hedge funds.

CVS traded up $0.39 during trading on Friday, hitting $63.99. The stock had a trading volume of 7,119,461 shares, compared to its average volume of 10,862,482. The firm has a market capitalization of $82.82 billion, a P/E ratio of 9.04, a PEG ratio of 1.39 and a beta of 0.85. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.64 and a current ratio of 0.95. CVS Health has a twelve month low of $51.72 and a twelve month high of $82.15. The company’s 50-day moving average price is $59.26 and its 200 day moving average price is $55.85.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Further Reading: Which market index is the best?

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.